COMMUNIQUÉS West-GlobeNewswire

Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
30/09/2026
NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a clinical stage biotechnology company focused on developing highly selective [...]
Oculis Announces Resignation of Lionel Carnot from Board of Directors
30/09/2026
Oculis Announces Resignation of Lionel Carnot from Board of Directors ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company [...]
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
30/09/2026
GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option [...]
COBRA Alternatives After Job Loss: How Healthcare Sharing Membership Works
30/09/2026
Healthcare sharing memberships enroll year-round, without an open enrollment window or COBRA-style election deadline. After a job loss, individuals and households typically weigh four options: the full COBRA premium, an [...]
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026
30/09/2026
Company announcement – No. 51 / 2026 Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 Copenhagen, Denmark, September 30, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") ( [...]
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
30/09/2026
Conference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026 BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel [...]
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
30/09/2026
Clinical trial designed to demonstrate proof-of-concept for soquelitinib in the treatment of hidradenitis suppurativa and evaluate its effects on Th17 biology SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE [...]
Scienture Holdings, Inc. Announces Reverse Stock Split
30/09/2026
COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to [...]
Longeveron to Participate in Three Longevity/Aging Investment Conferences
30/09/2026
New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce Neuroinflammation in the Brain, A Core Driver of AD Pathogenesis, Published on medRxiv MIAMI [...]
Atsena Presents Positive 18-Month Results from Part A of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
30/09/2026
18-month results from Part A of LIGHTHOUSE Trial reinforce ATSN-201’s favorable safety profile and durable structural and functional benefits in patients with X-linked retinoschisis Pivotal Part C cohort enrollment [...]
Abivax présentera des données sur l’obéfazimod lors de l’United European Gastroenterology (UEG) Week 2026
30/09/2026
Abivax présentera des données sur l’obéfazimod lors de l’United European Gastroenterology (UEG) Week 2026 Quatre présentations orales et trois posters s’appuient sur les données issues des programmes de maintenance et d [...]
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
30/09/2026
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long [...]
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
30/09/2026
Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. ( [...]
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
30/09/2026
Both previously disclosed Nasdaq compliance matters are now closed WARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN ), an integrated healthcare enterprise [...]
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
30/09/2026
TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer. Mr. Rogasik will lead a global business that [...]
Standard BioTools Provides Update on Sale of Mass Cytometry Business
30/09/2026
Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Venture, After Determining GMT Venture’s Unsolicited Acquisition Proposal as Superior BOSTON, Mass., Sept. 30, 2026 ( [...]
Oculis Announces Resignation of Lionel Carnot from Board of Directors
30/09/2026
ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet [...]
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
30/09/2026
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a [...]
SK pharmteco annonce un investissement de plus de 200 millions de dollars aux États-Unis pour renforcer ses capacités de production de petites molécules et de peptides
30/09/2026
RANCHO CORDOVA, Californie, 30 sept. 2026 (GLOBE NEWSWIRE) -- SK pharmteco a annoncé aujourd’hui un plan d’investissement global de plus de 200 millions de dollars sur cinq ans destiné à étendre et à moderniser ses [...]

Pages